16 completed, 6 terminated, 6 unknown, 5 active not recruiting. 40 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 40 | Completed 16, Terminated 6, Unknown 6, Active not recruiting 5, Recruiting 4, Not yet recruiting 2, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
Follow Follicular Lymphoma: new trials by email Literature Review of Follicular Lymphoma trials Research Report on Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-11-13 |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma TQB2825 Injection, Rituximab Injection - Follicular Lymphoma | Phase 3 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 228 | 2025-11-01 | 2025-09-23 |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
| A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas Radiation (Standard), Radiation (Very low dose) - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 375 | 2025-06-09 | 2026-10-26 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Mosunetuzumab, Lenalidomide, Rituximab - Follicular Lymphoma | Phase 3 | Active not recruiting | The Lymphoma Academic Research Organisation | 790 | 2024-06-07 | 2026-09-25 |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi Radiotherapy, Radiotherapy plus Obinutuzumab - Follicular Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 190 | 2023-12-14 | 2026-09-08 |
| Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A) - Follicular Lymphoma | Phase 3 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 605 | 2021-12-01 | 2026-06-26 |
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. tafasitamab, rituximab, lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | Incyte Corporation | 654 | 2021-04-15 | 2026-09-04 |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Tazemetostat, Placebo oral tablet, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma | Phase 3 | Active not recruiting | Epizyme, Inc. | 599 | 2020-06-11 | 2026-10-05 |
| Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma DRL_RI (Proposed rituximab biosimilar), MabThera® - Follicular Lymphoma | Phase 3 | Completed | Dr. Reddy's Laboratories Limited | 317 | 2019-05-15 | 2024-01-22 |
| A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Vitamin D, Rituximab, Placebo - Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 3 | Completed | Jonathan Friedberg | 211 | 2017-09-07 | 2024-09-04 |
| Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Ibrutinib Oral Capsule, Placebo, Rituximab - Follicular Lymphoma | Phase 3 | Completed | Pharmacyclics LLC. | 445 | 2017-01-23 | 2026-03-17 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| Dose Optimization Study of Idelalisib in Follicular Lymphoma Idelalisib - Follicular Lymphoma | Phase 3 | Terminated | Gilead Sciences | 96 | 2016-01-14 | 2023-08-14 |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Duvelisib, Placebo, Rituximab - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 3 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma CT-P10, Rituxan - Follicular Lymphoma | Phase 3 | Completed | Celltrion | 258 | 2015-11-09 | 2021-04-08 |
| Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide - Follicular Lymphoma | Phase 3 | Unknown | Wuhan University | 120 | 2015-10-01 | 2015-12-14 |
Showing 20 of 40. Sign in to see all of them.
Lymphoma, Follicular (40) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (3) · Burkitt Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · Bronchiolitis Obliterans Syndrome (1) · Hepatitis B, Chronic (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1)
Hemic and Lymphatic Diseases (40) · Immune System Diseases (40) · Immunoproliferative Disorders (40) · Lymphatic Diseases (40) · Lymphoproliferative Disorders (40) · Neoplasms (40) · Neoplasms by Histologic Type (40) · Lymphoma (36) · Lymphoma, Non-Hodgkin (35) · Lymphoma, B-Cell (9) · Hematologic Diseases (8) · Leukemia, Lymphoid (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Chronic Disease (7)
Rituximab (25) · Cyclophosphamide (8) · Vincristine (7) · Bendamustine Hydrochloride (6) · Lenalidomide (6) · Prednisone (6) · Doxorubicin (5) · Prednisolone (4) · Drug Therapy (3) · Radiotherapy (3) · Transplantation, Autologous (3) · fludarabine (3) · ibrutinib (3) · Methylprednisolone (2) · R-CHOP protocol (2)
Fondazione Italiana Linfomi - ETS (3) · The Lymphoma Academic Research Organisation (3) · Celgene (2) · Lymphoma Study Association (2) · Medical College of Wisconsin (2) · SecuraBio (2) · Spectrum Pharmaceuticals, Inc (2) · Australasian Leukaemia and Lymphoma Group (1) · Azienda Ospedaliera San Giovanni Battista (1) · Celltrion (1) · Dr. Reddy's Laboratories Limited (1) · Epizyme, Inc. (1) · French Innovative Leukemia Organisation (1) · Gilead Sciences (1) · Incyte Corporation (1)
United States (17) · France (16) · Italy (15) · Australia (13) · Spain (13) · Poland (12) · United Kingdom (10) · Belgium (9) · Canada (8) · Germany (8) · South Korea (8) · China (7) · Greece (7) · Israel (7) · Turkey (Türkiye) (7)
Franck Morschhauser, MD, PhD (2) · Hagop Youssoufian, MD (2) · Alessandro Gianni (1) · Alessandro Pileri, MD (1) · Alessandro Pulsoni, MD (1) · Andrea Filippi, MD (1) · Andrew Pettitt, Professor (1) · Bertrand Coiffier, MD (1) · Brandon Imber, MD (1) · Catherine Sebban, MD (1) · Chan Cheah (1) · Corrado Tarella, MD (1)
PMID 39374535, PMID 41915772, PMID 10586336, PMID 18239086, PMID 18955565, PMID 21073974, PMID 21176949, PMID 22885164, PMID 25029908, PMID 25596266, PMID 28712941, PMID 29095677, PMID 29975623, PMID 30184451, PMID 30389036, PMID 31339826, PMID 31820339, PMID 32673385, PMID 33475736, PMID 33683917, PMID 34152584, PMID 34273598, PMID 34686445, PMID 35947804, PMID 37071836, PMID 37088401, PMID 37120135, PMID 39677358, PMID 39846144, PMID 40421128, PMID 40499012, PMID 40896460, PMID 41123227, PMID 41350757, PMID 41360064, PMID 41580147, PMID 42317205
2023 (2), U24CA076518 (2), 2008 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1), 2025 (1), R01CA214890 (1), U01HL069294 (1), U10HL069294 (1)